title: Childhood stage IV Hodgkin disease: therapeutic results of the Polish pediatric leukemia/lymphoma study group.
abstract: BACKGROUND
  The therapeutic management in patients with stage IV Hodgkin disease is still controversial.
  
  
  METHODS
  Among 783 children with Hodgkin disease treated from 1971 to 1996, 56 patients (7.3%) were diagnosed with stage IV. The treatment consisted of MVPP or MVPP/B-DOPA chemotherapy combined with involved-field radiotherapy in 50 children.
  
  
  RESULTS
  The results of treatment of stage IV patients were compared in the three sequential time periods, during which the therapy was modified. In these periods, the first complete remission was obtained in 67%, 86%, and 90% of children, respectively, and the 10-year event-free survival was 42%, 64%, and 85%, respectively.
  
  
  CONCLUSIONS
  Alternate multidrug chemotherapy combined with low-dose involved-field radiotherapy is at present a satisfactory therapeutic method in children with stage IV Hodgkin disease.
authors.affiliation: Department of Hematology, Polish-American Children's Hospital, Collegium Medicum, Jagiellonian University in Krakow.
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: A
authors.initials: A
authors.lastname: Moryl-Bujakowska
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: J
authors.initials: J
authors.lastname: Pisarek
authors.forename: D
authors.initials: D
authors.lastname: Soñta-Jakimczyk
authors.forename: A
authors.initials: A
authors.lastname: Janik-Moszant
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: B
authors.initials: B
authors.lastname: Sopyło
authors.forename: B
authors.initials: B
authors.lastname: Kołakowska-Mrozowska
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: M
authors.initials: M
authors.lastname: Kaczmarek-Kanold
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: S
authors.initials: S
authors.lastname: Skomra
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: T
authors.initials: T
authors.lastname: Newecka-Samól
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D011044:Poland; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011239:Prednisolone; D011241:Prednisone